Mylan Acquires Two Dermatological Products from Valeant

Mylan announced that it has acquired the abbreviated new drug application (ANDA) for Clindamycin Phosphate / Benzoyl Peroxide gel, the generic version of Valeant's BenzaClin, and a license to manufacture and market Fluorouracil 5%, the generic version of Valeant's Efudex Cream. Clindamycin Phosphate / Benzoyl Peroxide Gel 1%/5%, is indicated for the topical treatment of acne vulgaris. Fluorouracil 5% cream is indicated for the topical treatment of multiple actinic or solar keratoses and is also indicated for the treatment of superficial basal cell carcinomas when conventional methods are impractical.

For more information call (800) RX-MYLAN or visit www.mylan.com.